Described are compounds of the general formula (I)
and pharmaceutically acceptable salt thereof, in which R2, R3, W,and X have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.
enantioselective addition to aldehydes by using a titanium(IV) catalyst derived from a H8‐binaphthol derivative in the presence of [Ti(OiPr)4] and MgBr2. A range of functionalities, including olefin, chlorine atoms, protected alcohols, amides, and cyano groups, are tolerated in the present reaction, providing the corresponding functionalized alcohols in high yields and enantioselectivities (see scheme)
在[Ti(O i Pr)4 ]和MgBr 2存在下,使用衍生自H 8-联萘酚衍生物的钛(IV)催化剂,可以将官能化的烷基卤化锌用于醛的对映选择性加成反应。在本反应中可以耐受多种官能团,包括烯烃,氯原子,受保护的醇,酰胺和氰基,从而以高收率和对映选择性提供相应的官能化醇(参见方案)。
[EN] PROCESS FOR THE HYDROGENATION OF IMINES<br/>[FR] PROCÉDÉ D'HYDROGÉNATION D'IMINES
申请人:CHEMINOVA AS
公开号:WO2010094164A1
公开(公告)日:2010-08-26
A process is provided for the hydrogenation of imines with hydrogen under elevated pressure in the presence of iridium complexes as catalysts and one or more co-catalysts selected among compounds comprising a carbon-halogen bond. Further provided are novel ligands and metal complexes thereof useful for the catalytic hydrogenation of imines with hydrogen. The novel ligands are compounds of the formula (VII) or formula (VIII) in the form of racemates, mixtures of stereoisomers or optically pure stereoisomers, wherein the radicals are as defined in the specification.
A process is provided for the hydrogenation of imines with hydrogen under elevated pressure in the presence of iridium complexes as catalysts and one or more co-catalysts selected among compounds comprising a carbon-halogen bond. Further provided are novel ligands and metal complexes thereof useful for the catalytic hydrogenation of imines with hydrogen.
The novel ligands are compounds of the formula (VII) or formula (VIII) in the form of racemates, mixtures of stereoisomers or optically pure stereoisomers
wherein the radicals are as defined in the specification.
3,4,5-Substituted piperidines as therapeutic compounds
申请人:Herold Peter
公开号:US20070167433A1
公开(公告)日:2007-07-19
Use of compounds of the general formula (I)
and pharmaceutically acceptable salt thereof, in which R
1
, R
2
, R
3
, R
4
, W, X and Z, n and m have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.